{
  "$schema": "folio-library-entry/v1",
  "id": "10665-357088",
  "blocks": [
    {
      "id": "library/10665-357088/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "GUIDELINES FOR \nDIAGNOSING, PREVENTING AND \nMANAGING CRYPTOCOCCAL \nDISEASE AMONG ADULTS, \nADOLESCENTS AND CHILDREN \nLIVING WITH HIV\nGUIDELINES FOR \nDIAGNOSING, PREVENTING AND \nMANAGING CRYPTOCOCCAL \nDISEASE AMONG ADULTS, \nADOLESCENTS AND CHILDREN \nLIVING WITH HIV\nGuidelines for diagnosing, preventing and managing cryptococcal disease among adults, \nadolescents and children living with HIV\nISBN 978-92-4-005217-8 (electronic version) \nISBN 978-92-4-005218-5 (print version)\n© World Health Organization 2022\nSome rights reserved. This work is available under the Creative Commons Attribution-\nNonCom",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover, copyright page and table of contents of WHO's 2022 guidelines on diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV, including annexes on methods, evidence profiles and evidence-to-decision tables.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definition of key terms",
      "pageStart": 7,
      "pageEnd": 8,
      "target": "../sections/sec-000-definition-of-key-terms.md",
      "narrative": null,
      "content": "Age groups\nThe following definitions for adults, adolescents, children and infants are used in these \nguidelines for the purpose of implementing recommendations for specific age groups. \nCountries may have other definitions under national laws.\n•\t An adult is a person older than 19 years of age.\n•\t An adolescent is a person 10–19 years of age inclusive.\n•\t A child is a person one year to younger than 10 years of age.\n•\t An infant is a child younger than one year of age.\nAdvanced HIV disease\nFor adults, adolescents and children five years or older, advanced HIV disease is defined \nas a CD4 cell",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the age groups used in the cryptococcal disease guidelines and terms such as advanced HIV disease, cryptococcal antigen positivity, cryptococcal infection and disease, relapse, sustained clinical response and treatment failure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 8,
      "pageEnd": 11,
      "target": "../sections/sec-001-acknowledgements.md",
      "narrative": null,
      "content": "WHO gratefully acknowledges the contributions of many individuals and organizations to \nupdate these guidelines.\nGuideline Development Group\nCo-Chairs: Alexandra Calmy (Hôpitaux Universitaires de Genève, Switzerland) and Nelesh \nGovender (National Institute for Communicable Diseases and University of the Witwatersrand, \nSouth Africa).\nEduardo Arathoon (Hospital General San Juan de Dios, Guatemala), Mohamed Chakroun \n(Fattouma Bourguiba Teaching Hospital, Tunisia), Rachel Burke (Malawi Liverpool Wellcome \nClinical Research Programme and London School of Hygiene & Tropical Medicine, Malawi), \nTo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Thanks the individuals and organizations who contributed to updating the cryptococcal disease guidelines, listing the Guideline Development Group, reviewers, WHO staff and regional offices. It notes that Unitaid funded the work.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 11,
      "pageEnd": 17,
      "target": "../sections/sec-002-executive-summary.md",
      "narrative": null,
      "content": "Cryptococcal disease is one of the most common opportunistic infections among people living \nwith advanced HIV disease and is a major contributor to illness, disability and mortality (1).\nBy far the most common presentation is cryptococcal meningitis, which caused an estimated \n223 100 incident cases and 181 100 deaths among people living with HIV in 2014 and \naccounted for 15% of all the people dying from HIV-related deaths globally (2). Cryptococcal \ndisease is uncommon among children with HIV.\nA public health approach leading to the prevention, earlier diagnosis and improved treatment \nof c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the burden of cryptococcal disease in advanced HIV, noting an estimated 181,100 deaths from cryptococcal meningitis in 2014, and explains that these guidelines replace the 2018 edition. It presents the main recommendations on diagnosis, antigen screening, preventive fluconazole and the new preferred induction regimen based on 2021 evidence. The summary also covers consolidation and maintenance treatment, deferred ART, managing raised intracranial pressure and steps for handling relapse.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-003-1-background.md",
      "narrative": null,
      "content": "Cryptococcal disease is one of the most important opportunistic infections among people living \nwith advanced HIV disease and is a major contributor to illness, disability and mortality (1–5). \nClinically significant invasive disease is primarily caused by reactivation of latent infection \namong immunocompromised individuals, such as people living with HIV, months to years after \ninitial exposure (6).\nBy far the most common presentation, representing up to 90% of HIV-related cryptococcal \ndisease, is cryptococcal meningitis, which caused an estimated 223 100 cases and 181 100 \ndeaths among peo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the background to cryptococcal disease as an opportunistic infection in advanced HIV, its high mortality especially in low-income countries, and the 2021 trial that prompted the update. It notes that the disease is uncommon in children and mostly presents as meningitis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Objectives and target audience",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-004-11-objectives-and-target-audience.md",
      "narrative": null,
      "content": "The objective of these guidelines is to provide updated, evidence-informed recommendations \nfor treating adults, adolescents and children living with HIV who have cryptococcal disease. \nThese guidelines are aimed at HIV programme managers, policy-makers, national treatment \nhealth care professionals and people living with HIV. \n2\nGuidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that the guidelines aim to give updated recommendations on treating cryptococcal disease in people with HIV and are intended for programme managers, policy-makers, clinicians and people living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guiding principles",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-005-12-guiding-principles.md",
      "narrative": null,
      "content": "The following principles have informed the development of these guidelines and should guide \nthe implementation of the recommendations.\n•\tThe guidelines are based on a public health approach to scaling up the use of antiretroviral \ndrugs along the continuum of HIV prevention, care and treatment.\n•\tRapid ART initiation regardless of CD4 cell count or immune status is the most important \npreventive strategy to reduce the incidence of opportunistic infections.\n•\tEarly diagnosis and prompt initiation of optimal antifungal treatment is essential to \nimproving survival and clinical and nervous syste",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the guiding principles behind the guidelines, such as rapid ART initiation, early diagnosis and antifungal treatment, and deferring ART after a positive antigen screen or confirmed meningitis. It adds that implementation should reflect local epidemiology and context.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnosing cryptococcal disease",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-006-21-diagnosing-cryptococcal-disease.md",
      "narrative": null,
      "content": "The 2018 WHO recommendations for diagnosing cryptococcal disease remain unchanged (16).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that WHO's 2018 recommendations on diagnosing cryptococcal disease remain unchanged.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-007-211-background.md",
      "narrative": null,
      "content": "Early diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \ncryptococcal disease. Health-care professionals should have a low threshold for suspecting \ncryptococcal meningitis among people with advanced HIV disease. National programmes  \nshould give priority to reliable access to rapid diagnostic cryptococcal antigen assays, \npreferably lateral flow assays, for use in cerebrospinal fluid (CSF), serum, plasma or whole \nblood. In addition, health-care professionals need to have a low threshold for suspecting \ncryptococcal meningitis.\nDiagnosis of cryptococcal meni",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses early diagnosis of cryptococcal meningitis and sets out the 2018 recommendation for prompt lumbar puncture with opening pressure measurement and rapid antigen testing. It describes diagnostic approaches according to access to lumbar puncture and rapid tests and lists contraindications to lumbar puncture.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007\u0007RECOMMENDATIONS ON DIAGNOSING AND PREVENTING CRYPTOCOCCAL DISEASE",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-008-2-recommendations-on-diagnosing-and-preventing-c.md",
      "narrative": null,
      "content": "PREVENTING CRYPTOCOCCAL DISEASE\n4\nGuidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV\nSummary of the diagnostic approach to cryptococcal meningitis\nLumbar puncture available\nLumbar puncture not available or \ncontraindicated\nRapid cryptococcal antigen test \navailable\nCSF cryptococcal antigen (preferably \nlateral flow assay)\nSerum, plasma or whole-blood \ncryptococcal antigen (preferably \nlateral flow assay), treat immediately \nand refer for further investigation\nNo rapid cryptococcal antigen test \navailable\nCSF India ink",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A summary chart of the diagnostic approach to cryptococcal meningitis, depending on whether lumbar puncture and rapid antigen tests are available.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for the recommendations",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/sec-009-212-rationale-for-the-recommendations.md",
      "narrative": null,
      "content": "Rapid cryptococcal antigen assay in CSF, serum, plasma or whole blood (depending on access \nto lumbar puncture) is preferred based on the much higher diagnostic accuracy of these rapid \ncryptococcal antigen assays versus the India ink test and the fact that these rapid assays \ndepend less on the health-care provider’s skills. Advantages of the lateral-flow assay over the \nlatex agglutination assay include its rapid (<10 minutes) turnaround time, cost–effectiveness, \nminimal training requirements and laboratory infrastructure, no need for refrigerated storage \nand higher clinical and analytical",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that rapid cryptococcal antigen assays are preferred over India ink because they are more accurate and need less skill, and why lateral-flow assays are favoured. It notes that blood antigen testing does not replace lumbar puncture where feasible and that the adult recommendations are extended to children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preventing and screening for cryptococcal disease",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/sec-010-22-preventing-and-screening-for-cryptococcal-dis.md",
      "narrative": null,
      "content": "The 2018 WHO recommendations for prevention and screening for cryptococcal disease remain \nunchanged (16).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that WHO's 2018 recommendations on preventing and screening for cryptococcal disease remain unchanged.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-011-221-background.md",
      "narrative": null,
      "content": "Early diagnosis and initiation of antiretroviral therapy remains the most important preventive \nstrategy to reduce the incidence of cryptococcal disease among people living with HIV and the \nassociated high mortality.2 Screening for cryptococcal antigenaemia is the optimal approach \nfor guiding resources in a public health approach and is the preferred approach for identifying \ninfection when managing people aged 10 years or older presenting with advanced HIV disease \n(20). There remains a role for fluconazole primary prophylaxis in settings in which cryptococcal \nantigen screening is not avai",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that early ART is the main way to prevent cryptococcal disease and sets out the 2018 recommendations on antigen screening before ART, pre-emptive antifungal therapy and fluconazole prophylaxis where screening is unavailable. It stresses evaluating everyone who screens positive for meningitis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for the recommendations",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-012-222-rationale-for-the-recommendations.md",
      "narrative": null,
      "content": "Since 2018, WHO guidelines have recommended that all adults and adolescents living with \nHIV who have a CD4 cell count <100 cells/mm3 be screened for cryptococcal antigen before \nART initiation or reinitiation; cryptococcal antigen screening may also be considered for \nadults and adolescents living with HIV who have a CD4 cell count <200 cells/mm3. These \nrecommendations were supported by evidence favouring the clinical benefit and cost–\neffectiveness of cryptococcal antigen screening (20,22,24–30). All individuals screening \npositive for cryptococcal antigen should be given pre-emptive antifu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the rationale for screening adults and adolescents with low CD4 counts for cryptococcal antigen before ART and for pre-emptive fluconazole in those who test positive. It covers evaluating antigen-positive people for meningitis and when to stop primary fluconazole prophylaxis, citing trials.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Recommendations for children",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-013-223-recommendations-for-children.md",
      "narrative": null,
      "content": "These recommendations apply to adults and adolescents with advanced HIV disease. The \ndecision not to extend these recommendations to children was based on the recognition that \ncryptococcal disease in this age group is rare, even in countries with high incidence (4,10).\nThese 2022 guidelines provide a new recommendation for the preferred antifungal regimen \nfor the induction phase of treatment.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the screening and prophylaxis recommendations are not extended to children because the disease is rare in them, and introduces the new 2022 induction recommendation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-014-31-background.md",
      "narrative": null,
      "content": "The 2018 WHO guidelines recommended seven days of amphotericin B deoxycholate and \nflucytosine-based therapy (followed by seven days of fluconazole 1200 mg) as the preferred \nantifungal regimen for the induction phase of treatment of HIV-associated cryptococcal \nmeningitis. This was a strong recommendation based on moderate-certainty evidence for \nadults and low-certainty evidence for children and adolescents (3). Liposomal amphotericin \nB is preferred over amphotericin B deoxycholate because of better tolerability. The guidelines \nrecommended the following as alternative options considering a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the 2018 induction regimens for cryptococcal meningitis based on amphotericin B and flucytosine, along with alternatives when drugs are unavailable, and the extrapolation of evidence to children. It notes that fluconazole monotherapy is not recommended and that WHO met in 2022 to consider a single high-dose liposomal amphotericin B regimen.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007\u0007RECOMMENDATIONS ON INDUCTION, CONSOLIDATION AND MAINTENANCE ANTIFUNGAL TREATMENT REGIMENS",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-015-3-recommendations-on-induction-consolidation-and.md",
      "narrative": null,
      "content": "CONSOLIDATION AND MAINTENANCE \nANTIFUNGAL TREATMENT REGIMENS\n8\nGuidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the recommendations on induction, consolidation and maintenance antifungal treatment regimens.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Induction therapy",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-016-32-induction-therapy.md",
      "narrative": null,
      "content": "Induction therapy (2022 recommendations)\nA single high dose (10 mg/kg) of liposomal amphotericin B with 14 days of flucytosine (100 mg/kg per day divided into \nfour doses per day) and fluconazole (1200 mg/daily for adults; 12 mg/kg per day for children and adolescents up to a \nmaximum of 800 mg daily) should be used as the preferred induction regimen for treating people with cryptococcal \nmeningitis.  \nStrong recommendation; moderate-certainty evidence for adults and low-certainty evidence for children\nAlternative induction regimens\nIf liposomal amphotericin B is not available:  \nA seven-day c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the 2022 recommendation of a single high dose of liposomal amphotericin B with 14 days of flucytosine and fluconazole as preferred induction therapy for cryptococcal meningitis. It lists alternative regimens for when liposomal amphotericin B, any amphotericin or flucytosine is unavailable and stresses the value of flucytosine.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for the recommendations",
      "pageStart": 24,
      "pageEnd": 27,
      "target": "../sections/sec-017-321-rationale-for-the-recommendations.md",
      "narrative": null,
      "content": "A systematic review from 2022 identified one randomized trial comparing a single high dose \nof liposomal amphotericin B, combined with oral flucytosine and fluconazole for 14 days, \ncompared with the preferred induction therapy recommended by WHO in 2018 (38).\nThe trial, conducted in Botswana, Malawi, South Africa, Uganda and Zimbabwe, enrolled 844 \nindividuals with HIV-associated cryptococcal meningitis who were randomized 1:1 to either \nsingle, high-dose liposomal amphotericin B 10 mg/kg given with 14 days of flucytosine 100 \nmg/kg per day and fluconazole 1200 mg/day (liposomal amphotericin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews the randomized trial in five African countries that compared single high-dose liposomal amphotericin B with the 2018 standard regimen in 844 people with cryptococcal meningitis. It reports that 10-week mortality was 24.8% versus 28.7%, showing non-inferiority, with fewer serious adverse events such as anaemia and kidney toxicity. The section also weighs costs, feasibility, acceptability and equity, noting the reduced burden on health workers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preventing, monitoring and managing amphotericin B deoxycholate toxicity",
      "pageStart": 27,
      "pageEnd": 30,
      "target": "../sections/sec-018-33-preventing-monitoring-and-managing-amphoteric.md",
      "narrative": null,
      "content": "deoxycholate toxicity\nManaging toxicity (2022 good practice principles)\nInfusion-related toxicity and side-effects from amphotericin B therapy are barriers to optimal induction treatment, \nespecially in low- and middle-income countries.\n• Safe administration of amphotericin B should be given priority and may require referral to a centre with access to the \nrecommended package of preventing, monitoring and managing toxicity.\n•\t Liposomal amphotericin B has fewer risks of drug toxicity than amphotericin B deoxycholate and requires a less \nintensive package for preventing, monitoring and managing",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out good practice principles for preventing, monitoring and managing amphotericin B toxicity, such as hypokalaemia, nephrotoxicity and anaemia. It describes pre-hydration, electrolyte supplementation and laboratory monitoring, and how to weigh continuing deoxycholate treatment when severe anaemia develops.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Drug interactions",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/sec-019-34-drug-interactions.md",
      "narrative": null,
      "content": "Drug interactions in the context of concurrent use of amphotericin, flucytosine and fluconazole \nalongside ART regimens have not been well documented (45).\nHowever, individuals receiving tenofovir disoproxil fumarate (TDF)–based regimens who are \nreceiving amphotericin or recently received amphotericin B preparations should be closely \nmonitored for nephrotoxicity. Liposomal preparations of amphotericin B are considered to be \nsafer (46) than deoxycholate but would still require close follow-up. The dose of TDF should be \nadjusted for renal function.\nFlucytosine, following its absorption and m",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes possible interactions between antifungal drugs and ART, advising kidney monitoring and dose adjustment of tenofovir with amphotericin and haematological monitoring with flucytosine.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Consolidation and maintenance treatment",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/sec-020-35-consolidation-and-maintenance-treatment.md",
      "narrative": null,
      "content": "The 2018 WHO recommendations for consolidation and maintenance treatment for cryptococcal \ndisease remain unchanged (16).\nConsolidation (2018 recommendation)\nRecommendation  \nFluconazole (800 mg daily for adults, 6–12 mg/kg per day for children and adolescents up to a maximum of 800 mg \ndaily) is recommended for the consolidation phase (for eight weeks following the induction phase).  \nStrong recommendation; low-certainty evidence\nMaintenance (2018 recommendation)\nFluconazole (200 mg daily for adults, 6 mg/kg per day for adolescents and children) is recommended for the \nmaintenance phase until",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Restates the unchanged 2018 recommendations for fluconazole doses in the consolidation phase and in maintenance therapy until immune reconstitution.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for the recommendations",
      "pageStart": 30,
      "pageEnd": 31,
      "target": "../sections/sec-021-351-rationale-for-the-recommendations.md",
      "narrative": null,
      "content": "WHO recommends fluconazole at 800 mg/day for eight weeks following an amphotericin B \ndeoxycholate–based induction regimen; these recommendations were based primarily on \nexpert opinion, considering the limited evidence from two trials that compared itraconazole \nversus fluconazole at lower doses (48,49). Recent guidelines from the European AIDS Clinical \nSociety recommend 400 mg for eight weeks after a single loading dose of 800 mg on the first \nday of therapy (50). Maintenance or secondary prophylaxis until there is evidence of sustained \nART-related immune reconstitution is an integral part",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the evidence behind fluconazole consolidation and maintenance doses and its role in preventing relapse. It also suggests expert-opinion regimens for localized non-meningeal disease, cryptococcomas and disseminated disease.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment for pregnant women",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../sections/sec-022-37-treatment-for-pregnant-women.md",
      "narrative": null,
      "content": "Amphotericin B therapy can be given to pregnant women with meningeal and non-meningeal \ndisease when the benefits outweigh the harm. Liposomal amphotericin B is considered as a \npregnancy category B drug and although animal reproduction studies have failed to demonstrate \na risk, an increase in spontaneous abortions was noted at higher doses. Exposure to flucytosine \nand fluconazole during pregnancy has been associated with an increased risk of birth defects in \nanimal studies and some uncontrolled human studies (60). The use of flucytosine and fluconazole \nfor treating cryptococcal disease am",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises that amphotericin B may be given in pregnancy when benefits outweigh harm, while flucytosine and fluconazole use should be judged case by case because of possible birth defects.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Adjunctive corticosteroids in treating HIV-associated cryptococcal meningitis",
      "pageStart": 31,
      "pageEnd": 32,
      "target": "../sections/sec-023-38-adjunctive-corticosteroids-in-treating-hiv-as.md",
      "narrative": null,
      "content": "cryptococcal meningitis\nAdjunctive corticosteroids (2018 recommendation)\nRoutine use of adjunctive corticosteroid therapy during the induction phase is not recommended in treating adults, \nadolescents and children who have HIV-associated cryptococcal meningitis.  \nStrong recommendation; high-certainty evidence for adults and adolescents and moderate-certainty evidence for children\n16\nGuidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV\nThe recommendation against the routine use of adjunctive corticosteroid therapy in the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Restates the 2018 recommendation against routine adjunctive corticosteroids during induction treatment of cryptococcal meningitis, citing trial evidence of more disability and adverse events. It notes that a paediatric advisory group found no reason for a different approach in children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Timing of ART initiation",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../sections/sec-024-39-timing-of-art-initiation.md",
      "narrative": null,
      "content": "Timing of ART (2018 recommendations)\nImmediate ART initiation is not recommended among adults, adolescents and children living with HIV who have \ncryptococcal meningitis because of the risk of increased mortality and should be deferred 4–6 weeks from the initiation \nof antifungal treatment.  \nStrong recommendation; low-certainty evidence for adults and very-low-certainty evidence for children and adolescents",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Restates the 2018 recommendation that ART be deferred 4–6 weeks after starting antifungal treatment for cryptococcal meningitis because immediate ART raises mortality.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for the recommendation",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../sections/sec-025-391-rationale-for-the-recommendation.md",
      "narrative": null,
      "content": "The optimal timing of ART after cryptococcal meningitis was informed by a systematic review \nthat identified four randomized controlled trials (62). Overall, early ART initiation increased \nmortality compared with delaying ART initiation (pooled relative risk for mortality at 6–12 \nmonths, 1.42, 95% CI 1.02–1.97). Immediately initiating ART is therefore not recommended \namong people with cryptococcal meningitis because of the potentially high risk of life-\nthreatening intracranial immune reconstitution inflammatory syndrome.\nWHO strongly recommends deferring ART initiation for four weeks follo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the evidence from four trials that early ART after cryptococcal meningitis increases mortality and specifies deferral periods depending on the induction regimen. It also discusses the limited evidence on ART timing for people who are antigen-positive without meningitis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implementation considerations",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../sections/sec-026-392-implementation-considerations.md",
      "narrative": null,
      "content": "ART-experienced people who develop cryptococcal meningitis should be evaluated for \npotential underlying ART treatment failure, ideally through confirmation by HIV viral load. \nART switches should be deferred by four weeks following an amphotericin B–based induction \nregimen or 4–6 weeks following a fluconazole-based induction regimen.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises evaluating people already on ART who develop cryptococcal meningitis for treatment failure and deferring any ART switch by four to six weeks.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring and managing people with cryptococcal meningitis",
      "pageStart": 33,
      "pageEnd": 33,
      "target": "../sections/sec-027-310-monitoring-and-managing-people-with-cryptoco.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Raised intracranial pressure",
      "pageStart": 33,
      "pageEnd": 35,
      "target": "../sections/sec-028-3101-raised-intracranial-pressure.md",
      "narrative": null,
      "content": "Initial measurement of intracranial pressure and management of raised intracranial pressure are \nan essential part of cryptococcal meningitis management to prevent death and serious nervous \nsystem complications. Raised intracranial pressure is a frequent and potentially life-threatening \ncomplication, occurring in up to 80% of people with HIV-associated cryptococcal meningitis. \nThe limitations of using clinical symptoms or signs to identify people suspected of having raised \nintracranial pressure requiring repeat therapeutic lumbar puncture has been recognized (15).\nReduction of raised CSF p",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that raised intracranial pressure affects up to 80% of people with HIV-associated cryptococcal meningitis and that lowering it improves survival. It recommends an initial and early repeat lumbar puncture with pressure measurement regardless of symptoms, with therapeutic drainage when pressure is high. Practical notes cover settings without manometers and the volume of fluid that can be removed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cryptococcal immune reconstitution inflammatory syndrome",
      "pageStart": 35,
      "pageEnd": 36,
      "target": "../sections/sec-029-3102-cryptococcal-immune-reconstitution-inflamma.md",
      "narrative": null,
      "content": "Paradoxical cryptococcal immune reconstitution inflammatory syndrome is associated \nwith high mortality (13). The median time to onset in reported cohort studies is typically \n3–12 weeks after initiating ART (67). Raised intracranial pressure is a common feature of \ncryptococcal immune reconstitution inflammatory syndrome and an important contributor to \nhigh mortality (68). Multiple repeat lumbar puncture may be necessary. Optimizing antifungal \ntherapy and reinduction with an amphotericin B–based regimen is important if suboptimal \nantifungal treatment is considered to contribute to developi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes cryptococcal immune reconstitution inflammatory syndrome after starting ART and lists management steps: continue ART, control intracranial pressure, optimize antifungals and consider short-course steroids for life-threatening deterioration.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007\u0007IMPLEMENTATION CONSIDERATIONS",
      "pageStart": 36,
      "pageEnd": 38,
      "target": "../sections/sec-030-4-implementation-considerations.md",
      "narrative": null,
      "content": "Diagnosis\nDiagnosis is key to improving mortality from cryptococcal disease, and national programmes \nneed to give priority to reliable access to rapid diagnostic cryptococcal antigen assays, \npreferably lateral flow assays for use in CSF and serum or plasma. In addition, health-care \nprofessionals need to have a low threshold for suspecting cryptococcal meningitis.\nCountries should develop plans to improve access to rapid cryptococcal antigen assays, \ndepending on the cryptococcal burden. Health-care infrastructure and available resources will \ndetermine the comprehensiveness of access.\nThe r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses practical issues in implementing the guidelines, including access to rapid antigen assays, laboratory reflex screening and task sharing. It also covers access to essential antifungal medicines, especially flucytosine and liposomal amphotericin B, and adapting the toxicity monitoring package to available resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007\u0007RESEARCH NEEDS",
      "pageStart": 38,
      "pageEnd": 39,
      "target": "../sections/sec-031-5-research-needs.md",
      "narrative": null,
      "content": "Further research is needed to assess the value of cryptococcal antigen screening at CD4 cell \ncount thresholds between 100 and 200 cells/mm3, which has been suggested to save costs if \ncarried out in inpatient settings.\nHigh cryptococcal antigen titres (>160) in blood have been found to predict subclinical \nmeningitis. It has been suggested that blood titres could be used to predict meningitis in \nsettings in which lumbar puncture cannot be performed or in which providing lumbar puncture \nfor everyone screening cryptococcal antigen–positive is operationally challenging; the \nfeasibility of thi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists research needs, such as screening at CD4 counts of 100–200, using blood antigen titres to predict meningitis, managing relapse and integrating screening into advanced HIV care packages.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "UPDATING AND DISSEMINATION",
      "pageStart": 39,
      "pageEnd": 40,
      "target": "../sections/sec-032-6-updating-and-dissemination.md",
      "narrative": null,
      "content": "These guidelines will be launched as a web-based product for dissemination and will be \nsupported by peer-reviewed publications of the systematic review and other evidence on \nwhich these recommendations are based. These guidelines will also be incorporated into \nthe periodic updates of the WHO consolidated guidelines on HIV (75). The consolidated \nguidelines on HIV will be updated in full or in part based on regular scoping exercises of \navailable evidence and experience from country implementation that will guide and trigger \nthe need for new guidance. As the evidence base or user needs chan",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the guidelines will be disseminated, incorporated into consolidated HIV guidelines, adapted by countries and monitored through a WHO policy database.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 40,
      "pageEnd": 45,
      "target": "../sections/sec-033-references.md",
      "narrative": null,
      "content": "1. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy.\nGeneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/255884,\naccessed 9 March 2022).\n2. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden\nof disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis.\n2017;17:873–81.\n3. Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV-\nassociated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD005647.\n4. Ford N, Sh",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the cryptococcal disease guidelines, citing WHO guidance and studies on HIV-associated cryptococcal meningitis, followed by a table mapping recommendations to the evidence reviews.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ANNEX 1. Process for developing the guidelines",
      "pageStart": 45,
      "pageEnd": 48,
      "target": "../sections/sec-034-annex-1-process-for-developing-the-guidelines.md",
      "narrative": null,
      "content": "THE GUIDELINES\nWHO first published a rapid advice document on the diagnosis, prevention and management of \ncryptococcal disease in December 2011. \nIn 2018, WHO published guidelines in response to new evidence relating to preventing, screening \nand treating cryptococcal disease. In 2021, new evidence on induction therapy was published \nthat triggered a review of the evidence and a WHO guideline development process. A Guideline \nDevelopment Group meeting was held in February 2022 to review the evidence and formulate a \nrecommendation on the preferred induction regimen for treating people with cr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1 of the WHO cryptococcal disease guidelines outlines how they were developed, from the 2011 rapid advice and 2018 guidelines to a February 2022 Guideline Development Group meeting prompted by new evidence on induction therapy. It explains the use of GRADE to rate evidence certainty and set recommendation strength, and how evidence was summarized and presented. It also describes how declarations of interest from the Guideline Development Group and External Review Group were reviewed and managed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 48,
      "pageEnd": 49,
      "target": "../sections/sec-035-references.md",
      "narrative": null,
      "content": "1.\t Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose \nLiposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022. \n386(12):1109-1120.\n2.\t Lawrence DS, Tsholo K, Ssali A, Mupambireyi Z, Hoddinott G, Nyirenda D et al. The Lived \nExperience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth \nqualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal \nmeningitis. BMJ Open. 2021;11:e039191.\n3.\t Liposomal amphotericin B: solving the access puzzle. Geneva: Médecins Sans Fron",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A short reference list citing the trial of single-dose liposomal amphotericin B for cryptococcal meningitis, a related qualitative study protocol and an MSF report on access to liposomal amphotericin B.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Web Annex 1. Declarations of interest for the Guideline Development Group and External Peer Review Group",
      "pageStart": 49,
      "pageEnd": 53,
      "target": "../sections/sec-036-web-annex-1-declarations-of-interest-for-the-gui.md",
      "narrative": null,
      "content": "THE GUIDELINE DEVELOPMENT GROUP AND \nEXTERNAL PEER REVIEW GROUP\nGuideline Development Group members (n = 15)\nSex\nPercentage\nMale\n53%\nFemale\n47%\nRegion\nPercentage\nAfrican Region\n47%\nRegion of the Americas\n27%\nEuropean Region\n6%\nEastern Mediterranean Region\n6%\nSouth-East Asia Region\n6%\nWestern Pacific Region\n6%\nName\n1. Employment and \nconsulting\n2. Research support\n3. Investment interests\n4. Intellectual property\n5. Public statements and \npositions\n6. Additional information\n7. Tobacco products\nConflicts and  \nmanagement plan\nEduardo Arathoon, (Hospital \nGeneral San Juan de Dios, \nGuatemala)\n0\n0",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Web Annex 1 tabulates declarations of interest for the 15 Guideline Development Group members, with their sex and regional breakdown, and records full participation for those listed. The page ends with the title and authors of Web Annex B, a systematic review and GRADE profile on treatment of HIV-associated cryptococcal meningitis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abstract",
      "pageStart": 53,
      "pageEnd": 54,
      "target": "../sections/sec-037-abstract.md",
      "narrative": null,
      "content": "Objective: The purpose of this systematic review is to provide updated evidence on the preferred \ninduction therapy for treating people with HIV-associated cryptococcal meningitis, considering the \nmost recent evidence available, to inform the need for updates to WHO guidelines.\nDesign: Systematic review.\nMethods: We searched Medline via PubMed, EMBASE, the Cochrane Library and ClinicalTrials.\ngov for published or completed randomized clinical trials that evaluated induction treatment of \nfirst-episode HIV-associated cryptococcal meningitis from 9 July 2018 (date of last search) through \n1 Sep",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The abstract of a systematic review on induction therapy for HIV-associated cryptococcal meningitis, which found one trial of 844 people comparing a single high dose of liposomal amphotericin B plus flucytosine and fluconazole with seven days of amphotericin deoxycholate. It reports that the single-dose regimen was non-inferior for 10-week mortality and caused fewer severe adverse events.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 54,
      "pageEnd": 54,
      "target": "../sections/sec-038-background.md",
      "narrative": null,
      "content": "Cryptococcal meningitis is a leading cause of HIV-related mortality globally (1). A systematic review \nand network meta-analysis published in 2018 (2) provided evidence that, in resource-limited \nsettings, one-week intravenous amphotericin B deoxycholate and oral flucytosine induction therapy \nwas superior to other regimens that had been evaluated in clinical trials, and this formed the basis \nfor guidelines published by WHO (3). Despite this highly effective antifungal regimen, 10-week \nmortality in clinical trials is estimated to be about 35% (95% confidence interval (CI) 29–42%) and \nhigher",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the background to the review, noting that cryptococcal meningitis is a leading cause of HIV deaths and that even the 2018 WHO-recommended regimen leaves high mortality and toxicity. It cites a trial in five African countries showing a single high dose of liposomal amphotericin B with two oral antifungals to be as effective, which prompted this update.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 54,
      "pageEnd": 56,
      "target": "../sections/sec-039-methods.md",
      "narrative": null,
      "content": "Eligibility criteria\nWe included randomized controlled trials among people living with HIV with a first episode of \ncryptococcal meningitis evaluating induction regimens for treating people with cryptococcal \nmeningitis not currently recommended by WHO guidelines. The standard-of-care arm had to include \nan induction regimen recommended by the WHO guidelines, either one week of amphotericin \ndeoxycholate with flucytosine or two weeks of flucytosine plus fluconazole.\nWe excluded non-randomized studies. Additional exclusion criteria were laboratory or animal \nstudies, trials that did not evaluat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the review methods, including eligibility of randomized trials comparing new induction regimens with WHO-recommended ones in people with a first episode of HIV-associated cryptococcal meningitis. It lists outcomes such as 2- and 10-week mortality, fungal clearance and serious laboratory adverse events, and explains the statistical analysis and use of GRADE for certainty.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Results",
      "pageStart": 56,
      "pageEnd": 57,
      "target": "../sections/sec-040-results.md",
      "narrative": null,
      "content": "Study selection\nWe identified 301 publications through database searches and one additional publication in press \narising from an abstract from other sources (Fig. 1). After de-duplication, 276 records were available \nfor reviewing titles and abstracts. Of these 276 records, 267 were excluded since they were not \nrandomized clinical trials involving humans with results available. Nine records were available for \nfull text review, of which eight were excluded; four did not use flucytosine in the comparator arm, \nthree had been previously included in the previous systematic review and one was co",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports the study selection, in which one trial of 844 adults in Botswana, Malawi, South Africa, Uganda and Zimbabwe met the criteria, and describes its non-inferiority design. It summarizes the risk of bias and GRADE assessments, rating certainty low for mortality and fungal clearance and moderate for severe adverse events.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Discussion",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../sections/sec-041-discussion.md",
      "narrative": null,
      "content": "This updated review identified one study of 844 participants comparing a novel induction strategy \nfor treating people with a first episode of HIV-associated cryptococcal meningitis. In the single \nstudy included in this systematic review, single high-dose (10 mg/kg) liposomal amphotericin B with \nflucytosine and fluconazole was non-inferior to the WHO-recommended standard-of-care induction \ntherapy for HIV-associated cryptococcal meningitis, with significantly fewer adverse events. Based \non low-certainty evidence from one study, mortality within 10 weeks may be lower with single-\ndose liposo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses the findings, concluding that single high-dose liposomal amphotericin B with flucytosine and fluconazole was non-inferior to standard induction therapy with fewer adverse events. It notes the limitation of relying on one trial and differences between trial and routine settings, and states that WHO issued updated guidelines in March 2022 recommending the regimen, calling for wider access to the drugs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../sections/sec-042-acknowledgements.md",
      "narrative": null,
      "content": "RR is supported by the National Institute of Allergy and Infectious Diseases (K23AI138851, \nR01AI162181). The content is solely the responsibility of the authors and does not necessarily \nrepresent the official views of the United States Centers for Disease Control and Prevention.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An acknowledgement of US National Institute of Allergy and Infectious Diseases funding for one author, with a disclaimer about CDC views.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Fig. A1. Study selection",
      "pageStart": 57,
      "pageEnd": 58,
      "target": "../sections/sec-043-fig-a1-study-selection.md",
      "narrative": null,
      "content": "301 databases + 1 \nadditional source\n276 after de-\nduplication\n267 excluded: not RCT, no results, \nanimal studies\n8 excluded from full-text review\n4 non-flucytosine comparator arm\n3 previously reviewed\n1 non-HIV cryptococcal meningitis\n8 published RCTs  \n+ 1 unpublished\n1 RCT\nWeb Annex B. Systematic review and GRADE evidence profile on treatment strategies for HIV-associated cryptococcal meningitis\n42\nGuidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flow diagram of study selection for the cryptococcal meningitis review, showing how 302 records were narrowed to one included randomized trial.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Supplemental Fig. 1. Risk of bias summary",
      "pageStart": 58,
      "pageEnd": 58,
      "target": "../sections/sec-044-supplemental-fig-1-risk-of-bias-summary.md",
      "narrative": null,
      "content": "Random sequence generation (selection bias)\n\t\nAllocation concealment (selection bias)\n\t\nBlinding of participants and personnel (performance bias)\n\t\nBlinding of outcome assessment (detection bias)\n\t\nIncomplete outcome data (attrition bias)\n\t\nSelective reporting (reporting bias)\n\t\nOther bias\nJarvis 2022\n+\n+\n–\n–\n+\n+\n+",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A risk of bias summary for the single included trial (Jarvis 2022), showing low risk in most domains but not for blinding.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Appendix. Search strategy: utility and impact review",
      "pageStart": 58,
      "pageEnd": 59,
      "target": "../sections/sec-045-appendix-search-strategy-utility-and-impact-revi.md",
      "narrative": null,
      "content": "The following search terms were used:\n1.\t Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR \nhiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab]OR human immunodeficiency virus[tiab] OR human \nimmunedeficiency virus[tiab] OR human immunodeficiency virus[tiab] OR human immune-\ndeficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired \nimmunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired \nimmunodeficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired \nimmun*[tiab]) AND",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the PubMed search strategy for the review, combining terms for HIV, cryptococcal meningitis and antifungal or other relevant drugs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "GRADE evidence profile on updated systematic review of HIV-associated cryptococcal meningitis treatment strategies",
      "pageStart": 59,
      "pageEnd": 60,
      "target": "../sections/sec-046-grade-evidence-profile-on-updated-systematic-rev.md",
      "narrative": null,
      "content": "treatment strategies \nCertainty assessment\nSummary of findings\nNumber \nof \nstudies\nStudy \ndesign\nRisk  \nof bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nNumber of \npatients in \nintervention\nNumber of \npatients in \ncontrol\nRelative \neffect \n(95% CI)\nAbsolute \neffect (95% \nCI)\nCertainty\nImportance\n10-week mortality\n1\nRandomized \ntrial\nNot \nserious\nSeriousa\nNot serious\nSeriousb\nNone\n101/407 \n(24.8%)\n117/407 \n(28.7%)\nRR 0.863 \n(0.690 to \n1.080)\n39 fewer per \n1000 (89 fewer \nto 23 more)\nLow\nCritical\nEarly fungicidal activity\n1\nRandomized \ntrial\nNot \nserious\nSeriousa\nNot serious",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The GRADE evidence profile table for the single trial, summarizing 10-week mortality, early fungicidal activity and severe adverse events with relative and absolute effects and certainty ratings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 60,
      "pageEnd": 61,
      "target": "../sections/sec-047-references.md",
      "narrative": null,
      "content": "1.\t Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden \nof disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. \n2017;17:873–81.\n2.\t Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV-\nassociated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;(7):CD005647.\n3.\t Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, \nadolescents and children: policy brief. Geneva: World Health Organization; 2018 (https://apps.\nwho.int/iris/handle/10665/2604",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the systematic review, citing studies on the burden and treatment of HIV-associated cryptococcal meningitis, WHO guidance and methods resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Web Annex 3. Evidence-to-decision-making table",
      "pageStart": 61,
      "pageEnd": 61,
      "target": "../sections/sec-048-web-annex-3-evidence-to-decision-making-table.md",
      "narrative": null,
      "content": "ANNEX 4. EVIDENCE-TO-DECISION-MAKING \nTABLE",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading page for the evidence-to-decision-making table annex; the extracted heading reads Annex 4 although the block is titled Web Annex 3.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of judgements",
      "pageStart": 61,
      "pageEnd": 61,
      "target": "../sections/sec-049-summary-of-judgements.md",
      "narrative": null,
      "content": "Question\nJudgement\n1. \t Is the problem a priority?\nYes\n2. \t How substantial are the benefits? \nLarge\n3. \t How substantial is the harm? \nLarge to moderate \n4. \t What is the overall certainty of evidence? \nModerate\n5. \t What is the balance between benefits and harm? \nFavours intervention\n6. \t \u0007Is there important variability or uncertainty in patient \npreferences regarding the key outcomes? \nNo important uncertainty or variability \n7. \t How large are the resource requirements (costs)? \nVaries \n8. \t What is the certainty of evidence for the costs?\nLow \n9. \t Is the intervention cost-effective? \nPro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the evidence-to-decision judgements, such as large benefits, moderate certainty, likely cost-effectiveness and acceptability, leading to a strong recommendation for single high-dose liposomal amphotericin B as induction therapy for cryptococcal disease.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Detailed evidence-to-decision-making table",
      "pageStart": 61,
      "pageEnd": 64,
      "target": "../sections/sec-050-detailed-evidence-to-decision-making-table.md",
      "narrative": null,
      "content": "Factor\nExplanation and evidence\nJudgement\nCertainty of \nevidence\nA systematic review found one randomized controlled trial, and the evidence \nwas considered to be of moderate certainty. \nModerate\nBalance of \nbenefits \nversus harm\nThe evidence indicated that the single high-dose liposomal amphotericin \nregimen was non-inferior in terms of 10-week mortality to the current WHO-\nrecommended treatment of seven daily doses of amphotericin B deoxycholate \n(1 mg/kg/day) plus flucytosine (100 mg/kg/day) followed by seven days of \nfluconazole 1200 mg/day and that the liposomal amphotericin regimen was",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The detailed evidence-to-decision table for single high-dose liposomal amphotericin B, explaining judgements on certainty, balance of benefits and harms, and values and preferences drawn from qualitative data from trial sites. It also covers resource use, cost-effectiveness, acceptability, feasibility and equity, noting likely benefits for children and settings unable to give longer amphotericin courses. The page ends with the ISBN and WHO HIV department contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-357088/blocks/figure-img-p064-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 64,
      "pageEnd": 64,
      "target": "../images/img-p064-1.webp",
      "narrative": "draft",
      "content": "An ISBN barcode for the publication, labelled 9789240052178.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
